The 13 patients enrolled in the study showed high rates of HER2-specific sensitization for both IFN-γ-secreting CD4+ T cells (85%) and CD8+ T cells (80%) and induction of tumor-lytic antibodies. The gene discussed is ERBB2; the disease is neoplasm.